TWST — Twist Bioscience Share Price
0.000.00%
Last trade - 00:00- $2.39bn
- $2.12bn
- $312.97m
- 74
- 15
- 77
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.25 | ||
| Price to Tang. Book | 6.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.69% | ||
| Return on Equity | -37.73% | ||
| Operating Margin | -63.15% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 90.1 | 132.33 | 203.56 | 245.11 | 312.97 | 376.01 | 442.83 | 41.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
Directors
- Emily Leproust CHM (48)
- James Thorburn CFO (66)
- Patrick Weiss COO (51)
- Dennis Cho SVP (51)
- William Banyai SVP (67)
- Paula Green SVP (54)
- Angela Bitting SVP
- Steffen Hellmold SVP
- Martin Kunz SVP (51)
- Erin Smith SVP
- Siyuan Chen CTO
- Kevin Yankton CAO (55)
- Aaron Sato CSO
- Patrick Finn OTH (50)
- Robert Chess LED (64)
- Nicolas Barthelemy IND (56)
- Nelson Chan IND (60)
- Keith Crandell IND (61)
- Jan Johannessen IND (65)
- Xiaoying Mai IND (35)
- Robert Ragusa IND (62)
- Melissa Starovasnik IND (56)
- Last Annual
- September 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 4th, 2013
- Public Since
- October 31st, 2018
- No. of Shareholders
- 50
- No. of Employees
- 923
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 59,651,142
- Address
- 681 Gateway Blvd., SOUTH SAN FRANCISCO, 94080
- Web
- https://www.twistbioscience.com/
- Phone
- +1 8007190671
- Auditors
- Ernst & Young LLP
Upcoming Events for TWST
Q2 2025 Twist Bioscience Corp Earnings Release
Q3 2025 Twist Bioscience Corp Earnings Release
Similar to TWST
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Twist Bioscience share price?
As of Today at 23:50 UTC, shares in Twist Bioscience are trading at $40.11. This share price information is delayed by 15 minutes.
How has the Twist Bioscience share price performed this year?
Shares in Twist Bioscience last closed at $40.11 and the price had moved by +29.05% over the past 365 days. In terms of relative price strength the Twist Bioscience share price has outperformed the S&P500 Index by +19.12% over the past year.
What are the analyst and broker recommendations for Twist Bioscience?
The overall consensus recommendation for Twist Bioscience is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Twist Bioscience dividend yield?
Twist Bioscience does not currently pay a dividend.
Does Twist Bioscience pay a dividend?
Twist Bioscience does not currently pay a dividend.
When does Twist Bioscience next pay dividends?
Twist Bioscience does not currently pay a dividend.
How do I buy Twist Bioscience shares?
To buy shares in Twist Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Twist Bioscience?
As of the previous close price of $40.11, shares in Twist Bioscience had a market capitalisation of $2.39bn.
Where are Twist Bioscience shares listed?
Here are the trading details for Twist Bioscience:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TWST
What kind of share is Twist Bioscience?
Based on an overall assessment of its quality, value and momentum Twist Bioscience is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Twist Bioscience share price forecast for 2025?
The analyst consensus target price for shares in Twist Bioscience is $53.74. That is 33.98% above the last closing price of $40.11.
Analysts covering Twist Bioscience currently have a consensus Earnings Per Share (EPS) forecast of -$2.16 for the next financial year.
Find out moreWhat is the trend in the Twist Bioscience share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Twist Bioscience. Over the past six months, its share price has outperformed the S&P500 Index by +4.13%.
As of the last closing price of $40.11, shares in Twist Bioscience were trading -11.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Twist Bioscience PE Ratio?
The Twist Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $40.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Twist Bioscience?
Twist Bioscience's management team is headed by:
- Emily Leproust - CHM
- James Thorburn - CFO
- Patrick Weiss - COO
- Dennis Cho - SVP
- William Banyai - SVP
- Paula Green - SVP
- Angela Bitting - SVP
- Steffen Hellmold - SVP
- Martin Kunz - SVP
- Erin Smith - SVP
- Siyuan Chen - CTO
- Kevin Yankton - CAO
- Aaron Sato - CSO
- Patrick Finn - OTH
- Robert Chess - LED
- Nicolas Barthelemy - IND
- Nelson Chan - IND
- Keith Crandell - IND
- Jan Johannessen - IND
- Xiaoying Mai - IND
- Robert Ragusa - IND
- Melissa Starovasnik - IND